Table 3.
Demographic and clinical characteristics of cases with death or hepatic abnormalities and reported acetaminophen dose below 76 mg/kg.
| Case# | Source | Age | Sex | Panel score* | Reported daily dose (mg/kg/d) | Duration | Peak Transaminase | Comments |
|---|---|---|---|---|---|---|---|---|
| Fatal Case | ||||||||
| 41 | Man | 5 m | M | 95 | 9.4 | 2 doses | 10960 | Serum APAP 36 mg/L >24 hr post last dose |
| Non-Fatal Cases | ||||||||
| 53 | Lit | 3 m | NR | 50 | 23 | 2d | >2000 | 3 day diarrhea/viral illness |
| 56 | Lit | 5m | RM | 50 | 42 | 2d | >2000 | 3 weeks of fever, viral illness |
| 110 | FDA | 2 y | M | 30 | 50–75 | 14 d | 230 IU/L | Given 4–6 doses/day of APAP product for up to 2 weeks for treatment of mastoiditis. |
| 112 | Lit | 2 y | M | 90 | 60 mg | 1 d | 36,755 | Hydrocephalus, admitted for UTI received APAP in hospital, long chain 3 hyoxyacyl CoA dehydrogenase deficient |
| 123 | PC | 3 | F | 85 | 80–160 | 2 d | 17000 | Hist prior liver failure, given either 4 × 80 or 4×160 mg tabs daily |
| 137 | PC | 4 y | M | 60 | 68# | 2.5 d | 799 | Fever, vomiting. Given adult formulation. |
| 138 | Lit | 4.5y | NR | 75 | 60 | 3 d | 5060 | |
| 139 | Lit | 4.5 | NR | 60 | 36 | 4 d | >2000 | 1 week fever, URI |
| 143 | PC | 5 y | m | 40 | 45.5# | 1 d | 8,000 IU/L | Nemalin Rod Neuropathy, ventilator dependent. 7 day illness- Received 2 doses (1g) of infant drop. Admitted for pneumonia with hepatic injury 2 days after APAP |
*
Panel score is a consensus score where the panel rated the probability that the liver injury or death was related to acetaminophen. 0= not acetaminophen 100= without a doubt acetaminophen.
#
Dose estimated using 90th percentile body weight for age and sex.